Mr. Paul Duffy reports

AI-ML APPOINTS DR. MARTIN GREEN TO MEDICAL ADVISORY BOARD AND ISSUE OPTIONS

AI-ML Innovations Inc. has appointed Dr. Martin Stephen Green, MD, FRCPC, professor emeritus at the University of Ottawa, to the company's medical advisory board, effective April 27, 2026.

Dr. Green joins the medical advisory board at the invitation of Dr. Paul Dorian, MD, MSc, the company's medical innovation architect and chair of the medical advisory board. The two physicians have collaborated for more than three decades across the Canadian Registry of Atrial Fibrillation (CARAF), the Canadian Cardiovascular Society guideline process and a series of peer-reviewed publications.

Dr. Green is a founding figure of Canadian cardiac electrophysiology (EP). He established the arrhythmia service at the University of Ottawa Heart Institute (UOHI) in 1983 as its sole electrophysiologist and built it into a national referral centre. He served as director of the EP fellowship program (1983 to 2017), director of the ECG (electrocardiography) department (1983 to 2018) and director of the inherited arrhythmia clinic (2013 to 2022). He trained under Prof. Hein J.J. Wellens at the University of Limburg in Maastricht and is a co-author of the 1984 Circulation paper on programmed ventricular stimulation that helped establish the field.

Dr. Green's appointment strengthens the clinical depth of AI-ML's medical advisory board as the company advances its product portfolio through clinical validation, regulatory engagement and commercial deployment.

Dr. Paul Dorian, chair of the AI-ML medical advisory board, commented: "Martin Green is one of the people who built modern cardiac electrophysiology in Canada. He has spent 45 years reading electrocardiograms and Holter recordings at a level very few physicians anywhere have matched, and he has trained much of the next generation. Inviting him to join our medical advisory board is one of the most consequential clinical additions AI-ML can make at this stage of its growth."

Dr. Green commented: "AI-ML is approaching ECG signal processing with the rigour that the underlying physiology requires. I am excited for the opportunity to help the company alongside Paul Dorian and the AI-ML team. I am honoured to accept the invitation to join the medical advisory board."

Paul Duffy, executive chairman and chief executive officer of AI-ML, commented: "Dr. Green's arrival on the medical advisory board, at Dr. Dorian's invitation, is a significant moment for AI-ML. He brings depth in electrocardiography and Canadian electrophysiology training, an extensive clinical research record, and direct experience with the limitations of the ECG platforms in clinical use today. With Dr. Green joined alongside Dr. Dorian, Dr. Rabinowitz, Dr. Connelly, Dr. Heilbron and Dr. Deyell, AI-ML's medical advisory board has strong clinical support to assist with the company's regulatory, scientific and commercial programs at the highest standard."

AI-ML established its medical advisory board in May, 2025, to guide clinical studies, regulatory strategy and real-world deployment of the company's AI-driven (artificial intelligence) ECG signal-processing platforms. Dr. Dorian was appointed medical innovation architect and head of the medical advisory board in January, 2026. With the addition of Dr. Green, AI-ML's medical advisory board now extends across three of Canada's principal cardiac centres -- St. Michael's Hospital (Toronto), St. Paul's Hospital (Vancouver) and the University of Ottawa Heart Institute (Ottawa) -- providing national clinical coverage in support of the company's continued growth.

About Dr. Green

Dr. Green is professor emeritus, faculty of medicine, University of Ottawa, and the recently retired cardiologist and cardiac electrophysiologist at the University of Ottawa Heart Institute.

Dr. Green received his medical degree from the University of Toronto in 1975, where he was awarded the K.J.R. Wightman Prize in Internal Medicine and the Cody Silver Medal. He completed internal medicine and cardiology training at the University of Ottawa, obtaining his FRCPC (medicine and cardiology) in 1981, and subsequently undertook a research fellowship in cardiac electrophysiology under Prof. Wellens at the University of Limburg, Maastricht, the Netherlands (1981 to 1983), funded by the Medical Research Council of Canada.

Returning to Ottawa in 1983, Dr. Green founded the UOHI arrhythmia service. He served as director of the arrhythmia service and electrophysiology laboratory (1983 to 2002 and 2007 to 2010), director of the EP fellowship program (1983 to 2017), director of the ECG department (1983 to 2018), and director of the inherited arrhythmia clinic (2013 to 2022). He chaired the board of governors of the UOHI academic medical organization from 2003 to 2016 and served on the executive of the Canadian Heart Rhythm Society (CHRS), including a decade-long tenure as chair of its education committee.

Dr. Green is the recipient of the 2010 Canadian Cardiovascular Society Distinguished Teacher Award and the 2022 Canadian Heart Rhythm Society Career Achievement Award. He has written or co-written more than 230 peer-reviewed publications, including the 1984 Circulation paper "Significance of ventricular arrhythmias initiated by programmed ventricular stimulation" (Brugada P., Green M., Abdollah H., Wellens H.J.J.) -- a foundational paper in sudden-death risk stratification. He is a long-standing investigator in the Canadian Registry of Atrial Fibrillation (CARAF I and II) and serves as chair of the events committee of the COAST-AF randomized controlled trial and chair of the data safety and monitoring committee of VIRTUES-CIED (CANet).

Dr. Green is co-editor, with Andrew Krahn (University of British Columbia) and Wael Alqarawi (UOHI/King Saud University), of the Springer textbook Electrocardiography of Inherited Arrhythmias and Cardiomyopathies: From Basic Science to Clinical Practice (Springer Nature, 2020). He has held editorial roles at the Canadian Journal of Cardiology, Heart Rhythm, the Journal of Electrocardiology, and the Indian Pacing and Electrophysiology Journal and has served as visiting faculty at meetings of the Indian Society of Electrocardiology and other international cardiology societies. He is a co-author of the 2024 Canadian Journal of Cardiology paper "Interpreting Wide-Complex Tachycardia With the Use of Artificial Intelligence."

Stock option grant

The company also announces that it has granted an aggregate of four million stock options to certain employees of the company, each exercisable to acquire one common share of the company at 10 cents for a period of five years.

About AI-ML Innovations Inc.

AI-ML Innovations is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health. The company's proprietary platforms leverage advanced signal processing and deep learning to convert complex biometric data into actionable clinical insights -- supporting earlier diagnosis, personalized treatment and more effective care.

AI-ML's shares trade on the Canadian Securities Exchange (symbol: AIML), the OTCQB Venture Market (symbol: AIMLF) and the Frankfurt Stock Exchange (symbol: 42FB).

We seek Safe Harbor.